Flagship Ventures Fund V General Partner LLC

Filings by Flagship Ventures Fund V General Partner LLC span 6 companies, the busiest being Kaleido Biosciences, Inc., Codiak BioSciences, Inc. and Foghorn Therapeutics Inc. In total, 36 filings cover trades dated from 11 May 2018 to 11 August 2023.

In open-market terms, that means 9 purchases worth €4.1M on one side and 2 sales worth €3.0M on the other. The totals exclude 1 filing filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. 2023 to date brings no purchases and 2 sales.

In size, the median ticket on the buying side is €339k. Clusters matter here: 4 out of 5 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

On 15 August 2023 came the latest disclosure, a transaction for €1.5M in Sigilon Therapeutics, Inc. The last insider purchase was made public on 16 September 2022, 1,496 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.